Clinical Trials

450 enrolled

Ovarian Neoplasms

NCT07286331 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

600 enrolled

Endometrial Neoplasms

NCT07604766 2026-05-22

RAINFOL-02

82 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07441681 2026-05-04

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07524257 2026-05-04

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07564141 2026-05-04

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

404 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07518147 2026-04-08

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

438 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05411237 2026-01-23

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

130 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

480 enrolled

Squamous Non-small Cell Lung Cancer

NCT06914011 2025-12-03

MRD2START

172 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06835400 2025-07-11

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

340 enrolled

Breast Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

50 enrolled

Stage III and IV Ovarian Cancer

NCT06870565 2025-03-17

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

238 enrolled

Uterine Cervical Neoplasms

NCT06867562 2025-03-10

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

166 enrolled

Platinum-Resistant Primary Peritoneal Carcinoma

NCT06795503 2025-01-28

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

1,462 enrolled

Triple Negative Breast Neoplasms

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

430 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

642 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

876 enrolled

Breast Neoplasms

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

368 enrolled

Recurrence

NCT05388500 2022-05-27

PHARE-C

800 enrolled

HER2-positive Breast Cancer

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

341 enrolled